- Home
- GMAB vs AGI Comparison
GMAB vs AGI Comparison
Compare GMAB & AGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- AGI
- Stock Information
- Founded
- GMAB 1999
- AGI 2003
- Country
- GMAB Denmark
- AGI Canada
- Employees
- GMAB N/A
- AGI N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- AGI Precious Metals
- Sector
- GMAB Health Care
- AGI Basic Materials
- Exchange
- GMAB Nasdaq
- AGI Nasdaq
- Market Cap
- GMAB 17.4B
- AGI 14.8B
- IPO Year
- GMAB N/A
- AGI 1999
- Fundamental
- Price
- GMAB $31.32
- AGI $34.71
- Analyst Decision
- GMAB Strong Buy
- AGI Strong Buy
- Analyst Count
- GMAB 6
- AGI 3
- Target Price
- GMAB $40.40
- AGI $41.00
- AVG Volume (30 Days)
- GMAB 1.8M
- AGI 3.4M
- Earning Date
- GMAB 11-06-2025
- AGI 10-29-2025
- Dividend Yield
- GMAB N/A
- AGI 0.29%
- EPS Growth
- GMAB 132.41
- AGI 112.89
- EPS
- GMAB 25.10
- AGI 1.28
- Revenue
- GMAB $3,845,670,022.00
- AGI $1,609,300,000.00
- Revenue This Year
- GMAB $24.92
- AGI $39.28
- Revenue Next Year
- GMAB $15.97
- AGI $27.13
- P/E Ratio
- GMAB $1.25
- AGI $27.18
- Revenue Growth
- GMAB 29.57
- AGI 31.30
- 52 Week Low
- GMAB $17.24
- AGI $17.80
- 52 Week High
- GMAB $33.65
- AGI $37.54
- Technical
- Relative Strength Index (RSI)
- GMAB 63.22
- AGI 59.67
- Support Level
- GMAB $29.98
- AGI $31.98
- Resistance Level
- GMAB $30.82
- AGI $35.07
- Average True Range (ATR)
- GMAB 0.65
- AGI 1.37
- MACD
- GMAB 0.15
- AGI 0.24
- Stochastic Oscillator
- GMAB 94.93
- AGI 93.42
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.